Read the latest press releases, news and events information from us, our parent company Cancer Research UK and our partners, including drug discovery...
Our dedicated blog showcases how we translate research from the lab bench to the bedside through stories from our scientists, dealmakers, and policy influencers.
The power of commercial data partnerships
27 February 2024
Iain Foulkes, CEO of Cancer Research Horizons, shares his thoughts on maximising the impact of patient-derived data through commercial partnerships that have clear benefits for people affected by cancer.
The UK spinout review: moving beyond equity
21 November 2023
The Government’s independent review of the UK spinout landscape reflects how well our universities commercialise their research, with some sensible suggestions on how to improve it further. Will ministers follow the recommendations or will the few loud voices urging to fix what isn’t broken drown out the data once again?
The emerging new drug class that nearly wasn’t
4 October 2023
MOv18, the first IgE antibody to enter clinical development, exemplifies the essential nature of our non-profit research-driven organisation in bringing truly ground-breaking advances to the treatment of cancer.
The Functional Genomics Centre: building a single-cell CRISPR capability
12 September 2023
The joint AstraZeneca–Cancer Research Horizons Functional Genomics Centre is collaborating with EMBL’s European Bioinformatics Institute to build its single-cell CRISPR capability. Find out how this technology advances drug discovery through genotype to phenotype correlation.
Chemistry on steroids: how we developed our expertise in steroid hydroxylation chemistry
25 July 2023
Review articles on synthetic chemistry aren’t the usual output of medicinal chemists. Yet a team of Cancer Research Horizons medicinal chemists have come to write a review on the hydroxylation of steroids, detailing discoveries in the beautiful and complicatedly chiral world of steroid chemistry.
The DETERMINE trial: showcasing Cancer Research UK’s unique position in the pharma industry
19 July 2023
Cancers that are diagnosed in fewer than 6 in 100,000 people each year are considered rare. Taken together, however, they account for 22% of all cancers diagnosed worldwide, more than any single type. Despite this, there are still far fewer treatments available for people with rare cancers. The DETERMINE trial aims to address that.